HOUSTON--(BUSINESS WIRE)-- Kiromic Biopharma, Inc. (Nasdaq: KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback